AbbVie (ABBV) Other Non Operating Income (2012 - 2026)
AbbVie (ABBV) reported Other Non Operating Income of -$2.3 billion for Q1 2026, down 59.58% year-over-year from -$5.7 billion in Q1 2025, and up 59.87% on a QoQ basis from -$5.7 billion in Q4 2025.
AbbVie (ABBV) has 15 years of Other Non Operating Income data on file, last reported at -$2.3 billion in Q1 2026.
- Quarterly Other Non Operating Income fell 59.58% year-over-year to -$2.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.2 billion (down 1172.05% YoY) and the FY2025 annual result came in at -$5.8 billion, down 27485.71% from the prior year.
- Other Non Operating Income rose to -$2.3 billion in Q1 2026 per ABBV's latest filing, from -$5.7 billion in the prior quarter.
- Across five years, Other Non Operating Income topped out at $3.1 billion in Q4 2024 and bottomed at -$5.7 billion in Q4 2025.
- The 5-year median for Other Non Operating Income is -$586.0 million (2024), against an average of -$1.0 billion.
- The widest annual swing landed in 2022, when Other Non Operating Income soared 8722.22%; it then plunged 2904.26% in 2023.
- Tracing ABBV's Other Non Operating Income over 5 years: stood at $279.0 million in 2022, then tumbled by 1741.58% to -$4.6 billion in 2023, then surged by 167.01% to $3.1 billion in 2024, then tumbled by 287.23% to -$5.7 billion in 2025, then surged by 59.87% to -$2.3 billion in 2026.
- Per Business Quant, the three latest ABBV Other Non Operating Income figures stand at -$2.3 billion (Q1 2026), -$5.7 billion (Q4 2025), and -$503.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.31 Bn |
| Dec 31, 2025 | -5.75 Bn |
| Sep 30, 2025 | -503.00 Mn |
| Jun 30, 2025 | -2.64 Bn |
| Mar 31, 2025 | -1.45 Bn |
| Dec 31, 2024 | 3.07 Bn |
| Sep 30, 2024 | -1.16 Bn |
| Jun 30, 2024 | -1.35 Bn |
| Mar 31, 2024 | -586.00 Mn |
| Dec 31, 2023 | -4.58 Bn |
| Sep 30, 2023 | 95.00 Mn |
| Jun 30, 2023 | -1.41 Bn |
| Mar 31, 2023 | -35.00 Mn |
| Dec 31, 2022 | 279.00 Mn |
| Sep 30, 2022 | 330.00 Mn |
| Jun 30, 2022 | -47.00 Mn |
| Mar 31, 2022 | 776.00 Mn |
| Dec 31, 2021 | -216.00 Mn |
| Sep 30, 2021 | -12.00 Mn |
| Jun 30, 2021 | -14.00 Mn |
| Mar 31, 2021 | -9.00 Mn |
| Dec 31, 2020 | -17.00 Mn |
| Sep 30, 2020 | -20.00 Mn |
| Jun 30, 2020 | -802.00 Mn |
| Mar 31, 2020 | -72.00 Mn |
| Dec 31, 2019 | 2.55 Bn |
| Sep 30, 2019 | -19.00 Mn |
| Jun 30, 2019 | -6.00 Mn |
| Mar 31, 2019 | -6.00 Mn |
| Dec 31, 2018 | -6.00 Mn |
| Sep 30, 2018 | -94.00 Mn |
| Jun 30, 2018 | -8.00 Mn |
| Mar 31, 2018 | 153.00 Mn |
| Dec 31, 2017 | -320.00 Mn |
| Sep 30, 2017 | -9.00 Mn |
| Jun 30, 2017 | -6.00 Mn |
| Mar 31, 2017 | -61.00 Mn |
| Dec 31, 2016 | -36.00 Mn |
| Sep 30, 2016 | 4.00 Mn |
| Jun 30, 2016 | -51.00 Mn |
| Dec 31, 2015 | 178.00 Mn |
| Sep 30, 2015 | -28.00 Mn |
| Jun 30, 2015 | 4.00 Mn |
| Mar 31, 2015 | -164.00 Mn |
| Dec 31, 2014 | 3.00 Mn |
| Sep 30, 2014 | 29.00 Mn |
| Jun 30, 2014 | -8.00 Mn |
| Mar 31, 2014 | 3.00 Mn |
| Dec 31, 2013 | 41.00 Mn |
| Sep 30, 2013 | -11.00 Mn |
| Jun 30, 2013 | 4.00 Mn |
| Mar 31, 2013 | -15.00 Mn |
| Dec 31, 2012 | 10.00 Mn |
| Sep 30, 2012 | -6.00 Mn |
| Jun 30, 2012 | -11.00 Mn |
| Mar 31, 2012 | -10.00 Mn |